<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900376</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00007-34</org_study_id>
    <nct_id>NCT04900376</nct_id>
  </id_info>
  <brief_title>Evaluation of Covid-19 Vaccination in Elderly Subjects in Retirement Home (EHPAD) and Long-term Care Units (USLD) in Ile-de-France</brief_title>
  <acronym>COGEVAX</acronym>
  <official_title>Evaluation of Covid-19 Vaccination in Elderly Subjects in Retirement Home (EHPAD) and Long-term Care Units (USLD) in Ile-de-France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gérond'if</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gérond'if</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this non-interventional, multi-center study is to compare the incidence&#xD;
      of serious health events (death, unscheduled hospitalizations) in subjects vaccinated against&#xD;
      Coronavirus with that of unvaccinated subjects, in Retirement Home (EHPAD) and Long-term Care&#xD;
      Units (USLD) in Ile-De-France during the same 12-month observation period.&#xD;
&#xD;
      The primary outcome will be the incidence of serious health events (death and unscheduled&#xD;
      hospitalizations) in subjects vaccinated against Coronavirus compared to that of unvaccinated&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study is a parallel cohort to the first phase of the vaccination campaign&#xD;
      against Coronavirus, in particular for elderly subjects in institutions. All subjects who&#xD;
      will not oppose the study will be included and this date will correspond to Day 0.&#xD;
&#xD;
      D0 will correspond to the date of the first vaccine injection for subjects in the vaccine&#xD;
      group.&#xD;
&#xD;
      The subjects included will be followed up on D21, D90, M6 and up to 12 months (M12).&#xD;
&#xD;
      The following data will be collected at inclusion and during follow-up:&#xD;
&#xD;
        -  Age, weight, sex, level of autonomy&#xD;
&#xD;
        -  Chronic diseases&#xD;
&#xD;
        -  Any hospitalizations&#xD;
&#xD;
        -  Possible symptoms after vaccination for subjects who choose to be vaccinated&#xD;
&#xD;
        -  The fate of the subjects and the evaluation of the immune response&#xD;
&#xD;
        -  Hospitalizations and vital status of subjects&#xD;
&#xD;
      Serology data prescribed by doctors as part of routine care will also be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the incidence of serious events in subjects vaccinated against CORONAVIRUS compared to those not vaccinated using their number, percentage and 95% confidence interval and methods of survival analysis Kaplan Meier and Cox model</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the incidence of geriatric syndromes using their number, percentage and 95% confidence interval and survival analysis methods: Kaplan Meier and Cox model</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating the Incidence of Organ Decompensations according Their Number, Percentage, and 95% Confidence Interval and Survival Analysis Methods: Kaplan Meier and Cox Model</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the incidence of serious and non-serious side effects using their number, percentage and 95% confidence interval and survival analysis methods: Kaplan Meier and Cox model. Kaplan Meier and Cox model</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the incidence of symptomatic and severe coronavirus in vaccinated and unvaccinated subjects using their number, percentage and 95% confidence interval and survival analysis methods: Kaplan Meier and Cox Model. Kaplan Meier and Cox model</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Carrying out adjustment analyzes by multivariate logistic regressions on confounding factors</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Performing propensity score analyzes to balance the vaccinated and unvaccinated groups</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4100</enrollment>
  <condition>Reside Either in Retirement Home or Long-term Care Units</condition>
  <arm_group>
    <arm_group_label>vaccinated group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>unvaccinated group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retirement Home (EHPAD) residents and Long-term Care Units (USLD) patients vaccinated or&#xD;
        not against Coronavivus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject in Retirement Home (EHPAD) or Long-term Care Units (USLD) during the&#xD;
             anti-Coronavivus vaccination period.&#xD;
&#xD;
          -  Subject not opposing the study or whose legal representative does not oppose the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject not affiliated to a social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hanon, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Geriatric Department, Broca hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Dufour</last_name>
    <phone>+33 (0)185781010</phone>
    <email>isabelle.dufour@gerondif.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrien Besseiche</last_name>
    <phone>+33 (0)185781010</phone>
    <email>adrien.besseiche@gerondif.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geriatric Department, Broca Hospital</name>
      <address>
        <city>Paris</city>
        <state>IIe-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hanon, MD PhD</last_name>
      <phone>+33 (0)144083503</phone>
      <email>olivier.hanon@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 22, 2021</study_first_submitted>
  <study_first_submitted_qc>May 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 22, 2021</last_update_submitted>
  <last_update_submitted_qc>May 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retirement Home (EHPAD)</keyword>
  <keyword>Long-term Care Units (USLD)</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Vaccination</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

